122 related articles for article (PubMed ID: 9053511)
1. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency.
Smith GA; Damon LE; Rugo HS; Ries CA; Linker CA
J Clin Oncol; 1997 Feb; 15(2):833-9. PubMed ID: 9053511
[TBL] [Abstract][Full Text] [Related]
2. The association between high-dose cytarabine neurotoxicity and renal insufficiency.
Damon LE; Mass R; Linker CA
J Clin Oncol; 1989 Oct; 7(10):1563-8. PubMed ID: 2778484
[TBL] [Abstract][Full Text] [Related]
3. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia.
Rubin EH; Andersen JW; Berg DT; Schiffer CA; Mayer RJ; Stone RM
J Clin Oncol; 1992 Jun; 10(6):948-53. PubMed ID: 1588374
[TBL] [Abstract][Full Text] [Related]
5. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
Kornblau SM; Cortes-Franco J; Estey E
Leukemia; 1993 Mar; 7(3):378-83. PubMed ID: 8445943
[TBL] [Abstract][Full Text] [Related]
6. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
7. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
[TBL] [Abstract][Full Text] [Related]
9. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
Byrd JC; Ruppert AS; Mrózek K; Carroll AJ; Edwards CG; Arthur DC; Pettenati MJ; Stamberg J; Koduru PR; Moore JO; Mayer RJ; Davey FR; Larson RA; Bloomfield CD
J Clin Oncol; 2004 Mar; 22(6):1087-94. PubMed ID: 15020610
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
11. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
[TBL] [Abstract][Full Text] [Related]
12. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Yee KW; Cortes J; Ferrajoli A; Garcia-Manero G; Verstovsek S; Wierda W; Thomas D; Faderl S; King I; O'brien SM; Jeha S; Andreeff M; Cahill A; Sznol M; Giles FJ
Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631
[TBL] [Abstract][Full Text] [Related]
13. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
[TBL] [Abstract][Full Text] [Related]
14. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
[TBL] [Abstract][Full Text] [Related]
15. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
Damon LE; Plunkett W; Linker CA
Cancer Res; 1991 Aug; 51(16):4141-5. PubMed ID: 1868435
[TBL] [Abstract][Full Text] [Related]
16. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S
Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
[TBL] [Abstract][Full Text] [Related]
17. High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia.
Cole N; Gibson BE
Blood Rev; 1997 Mar; 11(1):39-45. PubMed ID: 9218105
[TBL] [Abstract][Full Text] [Related]
18. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
[TBL] [Abstract][Full Text] [Related]
19. Ara-C fever and infections after high-dose ara-C treatment in pediatric lymphoid malignancies.
Ek T; Pinkava M; Abrahamsson J
J Pediatr Hematol Oncol; 2005 Jul; 27(7):364-9. PubMed ID: 16012325
[TBL] [Abstract][Full Text] [Related]
20. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia.
Heinemann V; Estey E; Keating MJ; Plunkett W
J Clin Oncol; 1989 May; 7(5):622-8. PubMed ID: 2709090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
